Clinical Trial

A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Study acronym: STAR-03
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To explore the efficacy of Iparomlimab and Tuvonralimab (QL1706) in combination with SOX chemotherapy versus chemotherapy alone for the neoadjuvant treatment of locally-progressed gastric/gastroesophageal union adenocarcinomas by evaluating the complete pathologic remission rate (pCR).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-11.
Status change: Not Yet Recruiting → Recruiting 2026-04-24
Trial Details
NCT Number NCT06829797
Lead Sponsor Shandong Provincial Hospital
Conditions Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment 96 participants
Start Date 2025-03-11
Primary Completion 2028-02-29 (estimated)
Study Completion 2028-02-29 (estimated)
Updated on ClinicalTrials.gov 2026-04-29